Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Status:
Not yet recruiting

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Phase 3

Polaris Group